The designation helps the firm accelerate the development and evaluation of CB-011.
Pitolisant will be assessed in 200 patients with idiopathic hypersomnia, using change in excessive daytime sleepiness as the primary end point.
Scientists from Japan reveal the crystal structure of a cell cycle motor protein, which could be a potential anticancer drug candidate
We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.